Los Angeles, CA, April 4, 2023 – US Fertility, the nation’s largest partnership of physician-owned fertility practices, and Ovation Fertility (“Ovation”), announced today that they have entered into a definitive agreement to combine and become the leading fertility company in the United States. The combined company’s enhanced platform will be well positioned to drive growth and innovation, while leveraging best practices to improve patient access, experience, and outcomes.
US Fertility is comprised of more than 120 physicians in highly experienced fertility centers across the country, with a network of clinics that perform 30,000 in-vitro fertilization (IVF) cycles annually. More than 130,000 individuals and couples have trusted USF to help them build their families with assisted reproductive technology.
Ovation is a leading network of fertility laboratories and affiliated physician practices committed to applying leading-edge treatment options to improve outcomes for patients. In addition to operating IVF laboratories, Ovation also provides ancillary services, including diagnostic testing, genetic testing, donor services, surrogacy, and cryogenic storage. The plan is for Ovation to continue operating under its unique physician partnership model to offer its IVF laboratory and ancillary services as a wholly owned subsidiary of US Fertility.
“We have a truly transformative opportunity to help more people build the families of their dreams by bringing together the core competencies of US Fertility and Ovation. By creating the leading fertility network in the US, we can utilize shared best practices to enhance the patient experience, provide outstanding care, and deliver improved research and innovation to the fertility industry. Collectively, the company will provide a platform for growth and expansion into additional life sciences verticals.,” said Richard Jennings, US Fertility CEO.
“Ovation is a highly complementary addition to the US Fertility network, which is built upon the pillars of scientific innovation, access to care, and clinical excellence. Together, US Fertility and Ovation will offer a full range of reproductive services and will continue to deliver exceptional outcomes in every stage of the personalized journey of building a family”, said Jaime Shamonki, US Fertility COO.
“As a combined company, US Fertility and Ovation will be an even stronger platform, to make strategic investments that advance our growth. In addition to the important clinical and innovation benefits this combination will provide to our patients, we will also create new and value-enhancing opportunities for all our shareholders,” said Joshua Saipe, US Fertility CFO.
“Bringing these two organizations together offers tremendous long-term opportunities for both companies, their physicians, and their employees. Most importantly, we expect this partnership to have a tremendous positive impact on patients, who will benefit from the combined company’s high standard of clinical expertise and favorable pregnancy outcomes. ” said Mark Segal, USF Chairman of the Board.
“By aligning with US Fertility and Amulet, we will be able to strengthen the purpose that unites our scientists, physicians, and clinical care teams—bringing the joy of parenthood to more families through innovative science. We will work side by side to establish better industry standards and contribute to worldwide fertility research,” said Paul Kappelman, Ovation CEO.
The transaction is expected to close in the second quarter of 2023, subject to customary closing conditions, including regulatory approval.